CR-001 in Adult Participants With Locally Advanced or Metastatic Solid Tumors

Key Inclusion Criteria * Life expectancy ≥ 3 months * Eastern Cooperative Oncology Group (ECOG) performance status score of 0 - 1 * Adequate organ function and hematologic reserve based on laboratory parameters * Have measurable disease defined by RECIST v1.1 * For Backfill, Dose Expansion and Dose Optimization: Willingness to provide recent archival tumor tissue sample or willingness to undergo biopsy * Tumor Indication specific inclusion criteria: * For dose escalation or backfill: progressing from, intolerant to, or ineligible for (due to unavailability or contraindication) local standard of care therapies and have one of the following locally advanced or metastatic tumor types: * Non-small cell lung cancer (NSCLC) * Hepatocellular carcinoma (HCC) * Biliary tract cancer (BTC) * Endometrial carcinoma * Cervical cancer * Ovarian cancer * Gastric or gastroesophageal cancer (GC/GEJ) * Colorectal cancer (CRC) * For dose expansion: have one of the following locally advanced or metastatic tumor types: * 1L Non-small cell lung cancer (NSCLC) * 1L Colorectal cancer (CRC) * 3L Colorectal cancer (CRC) * 1L Endometrial carcinoma * 1L Gastric or gastroesophageal cancer (GC/GEJ) * 2L Gastric or gastroesophageal cancer (GC/GEJ) * 1L Biliary tract cancer (BTC) Key Exclusion Criteria for all parts * Has malignancies other than disease under study within the past 3 years * Has conditions requiring treatment with clinically significant or increasing doses of systemic steroid therapy * Has not adequately recovered from recent major surgery * Has ongoing clinically significant toxicity related to prior therapy * Has active central nervous system (CNS) metastases * Has active autoimmune disease requiring systemic therapy in the past 2 years (replacement therapy is permitted) * Has a history of serious Grade ≥ 3 immune-related adverse event (irAE) * Has a history of noninfectious pneumonitis/interstitial lung disease * Has an active severe infection * Has received a live or attenuated vaccine within 30 days of the first dose * Has undergone prior allogeneic stem cell or solid organ transplantation * Has protocol-specified events related to gastrointestinal perforation, surgery, wound healing complications, and bleeding * Has clinically significant cardiovascular disease Key Exclusion Criteria for dose expansion only * Has received prior anti-PD-1/L1 treatment * Has history of hypersensitivity reaction to the cohort-specific combination agent(s) or its excipients * Has any contraindication to the cohort-specific combination agent(s) * Has Grade \>1 neuropathy at Screening NOTE: Other protocol defined Inclusion and Exclusion criteria may apply.